ArticleBMC bioinformatics2025
DTI-MHAPR: optimized drug-target interaction prediction via PCA-enhanced features and heterogeneous graph attention networks.
Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- In vitro α-glucosidase inhibition, molecular dynamics and docking study of phenyl carbamoyl methoxy thiosemicarbazone derivatives as potential anti-diabetic agents.Journal of enzyme inhibition and medicinal chemistry · 2025Article
- Enhancing drug repositioning: A multi-class ensemble model for drug-target interaction prediction with action type categorization.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Drug-target interactions (DTIs) are pivotal in drug discovery and development, and their accurate identification can significantly expedite the process. Numerous DTI prediction methods have emerged, yet many fail to fully harness the feature information of drugs and targets or address the issue of feature redundancy. We aim to refine DTI prediction accuracy by eliminating redundant features and capitalizing on the node topological structure to enhance feature extraction. To achieve this, we introduce a PCA-augmented multi-layer heterogeneous graph-based network that concentrates on key features throughout the encoding-decoding phase. Our approach initiates with the construction of a heterogeneous graph from various similarity metrics, which is then encoded via a graph neural network. We concatenate and integrate the resultant representation vectors to merge multi-level information. Subsequently, principal component analysis is applied to distill the most informative features, with the random forest algorithm employed for the final decoding of the integrated data. Our method outperforms six baseline models in terms of accuracy, as demonstrated by extensive experimentation. Comprehensive ablation studies, visualization of results, and in-depth case analyses further validate our framework's efficacy and interpretability, providing a novel tool for drug discovery that integrates multimodal features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.